{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1360011146022845440.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.bmc.2019.02.012"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0968089618317930?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0968089618317930?httpAccept=text/plain"}}],"dc:title":[{"@value":"Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380011146022845445","@type":"Researcher","foaf:name":[{"@value":"Mahmoud S. Abdelbaset"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011146022845442","@type":"Researcher","foaf:name":[{"@value":"Mohamed Abdel-Aziz"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011146022845440","@type":"Researcher","foaf:name":[{"@value":"Mohamed Ramadan"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011146022845446","@type":"Researcher","foaf:name":[{"@value":"Mostafa H. Abdelrahman"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011146022845441","@type":"Researcher","foaf:name":[{"@value":"Syed Nasir Abbas Bukhari"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011146022845444","@type":"Researcher","foaf:name":[{"@value":"Taha F.S. Ali"}]},{"@id":"https://cir.nii.ac.jp/crid/1380011146022845443","@type":"Researcher","foaf:name":[{"@value":"Gamal El-Din A. Abuo-Rahma"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"09680896"}],"prism:publicationName":[{"@value":"Bioorganic & Medicinal Chemistry"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2019-03","prism:volume":"27","prism:number":"6","prism:startingPage":"1076","prism:endingPage":"1086"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0968089618317930?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0968089618317930?httpAccept=text/plain"}],"createdAt":"2019-02-05","modifiedAt":"2025-10-19","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360853567666018944","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.bmc.2019.02.012"},{"@type":"CROSSREF","@value":"10.3390/molecules25215190_references_DOI_ZIV7dJkNKWsjDFSSUwO4igtaXBr"}]}